Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.10 USD | 0.00% |
|
+1.36% | +38.54% |
Jan. 31 | North American Morning Briefing : Investors in -2- | DJ |
Jan. 30 | Pacira BioSciences, Inc. Announces Board and Audit Committee Changes | CI |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Drug Delivery Systems | 421M | 430M | 542M | 667M | 675M | |||||
Total Assets | 831M | 1.27B | 2.08B | 1.68B | 1.57B | |||||
Interest Expense | -23.63M | -25.67M | -31.75M | -39.98M | -20.31M | |||||
Income Tax Expense | 268K | -125M | 14.42M | -2.61M | 19.75M | |||||
CAPEX | -10.16M | -37.8M | -45.87M | -30.08M | -15.16M | |||||
EBT | -10.75M | 20.09M | 56.4M | 13.3M | 61.7M | |||||
D&A | 13.88M | 19.91M | 28.55M | 81M | 75.57M | |||||
Operating Income | 10.48M | 46.35M | 89.92M | 60.02M | 87.68M | |||||
Net Income | -11.02M | 146M | 41.98M | 15.91M | 41.96M |
Geographical Revenue Distribution History
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
United States | 421M | 430M | 542M | 667M | 675M | |||||
Total Assets | 831M | 1.27B | 2.08B | 1.68B | 1.57B | |||||
Interest Expense | -23.63M | -25.67M | -31.75M | -39.98M | -20.31M | |||||
Income Tax Expense | 268K | -125M | 14.42M | -2.61M | 19.75M | |||||
D&A | 13.88M | 19.91M | 28.55M | 81M | 75.57M | |||||
CAPEX | -10.16M | -37.8M | -45.87M | -30.08M | -15.16M | |||||
Net Income | -11.02M | 146M | 41.98M | 15.91M | 41.96M | |||||
EBT | -10.75M | 20.09M | 56.4M | 13.3M | 61.7M | |||||
Operating Income | 10.48M | 46.35M | 89.92M | 60.02M | 87.68M | |||||
Foreign | - | - | - | - | - |
- Stock Market
- Equities
- PCRX Stock
- Financials Pacira BioSciences, Inc.
- Business Segments